Effect of olprinone, a phosphodiesterase III inhibitor, on hepatic ischemia-reperfusion injury in rats

Shock

Volumn 33, Issue 4, 2010, Pages 436-441

  Yamaguchi, Keisuke ^a   Kawahara, Toshiyasu ^a   Kumakura, Seiichiro ^b   Hua, Jian ^a   Kugimiya, Toyoki ^a   Nagaoka, Isao ^a   Inada, Eiichi ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JUNTENDO UNIVERSITY NERIMA HOSPITAL   (Japan)

Author keywords

Adhesion molecule; C Jun N terminal kinase; Cyclic adenosine monophosphate; Cytokine; I R injury; Liver; P38 mitogen activated protein kinase; Phosphodiesterase inhibitor

Indexed keywords

CYCLIC AMP; CYTOKINE INDUCED NEUTROPHIL CHEMOATTRACTANT; CYTOKINE INDUCED NEUTROPHIL CHEMOATTRACTANT 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LOPRINONE; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; IMIDAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; LIVER ISCHEMIA; LIVER LEVEL; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; ANIMAL; BIOSYNTHESIS; FISCHER 344 RAT; LIVER; METABOLISM; PATHOPHYSIOLOGY; REPERFUSION INJURY;

ANIMALS; CYCLIC AMP; IMIDAZOLES; INTERCELLULAR ADHESION MOLECULE-1; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LIVER; MALE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDONES; RATS; RATS, INBRED F344; REPERFUSION INJURY;

EID: 77954718667     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0b013e3181be3d7a     Document Type: Article

References (47)

1. Mizushige K, Ueda T, Yukiiri K, Suzuki H: Olprinone: a phosphodiesterase III inhibitor with positive inotropic and vasodilator effects. Cardiovasc Drug Rev 20:163-174, 2002.
2. Jaeschke H: Role of reactive oxygen species in hepatic ischemia-reperfusion injury and preconditioning. J Invest Surg 16:127-140, 2003.
3. Di Carlo I, Pulvirenti E, Toro A: Use of dissecting sealer may affect the early outcome in patients submitted to hepatic resection. HPB (Oxford) 10:271-274, 2008.
4. Casillas-Ramirez A, Mosbah IB, Ramalho F, Rosello-Catafau J, Peralta C: Past and future approaches to ischemia-reperfusion lesion associated with liver transplantation. Life Sci 79:1881-1894, 2006.
5. Husted TL, Lentsch AB: The role of cytokines in pharmacological modulation of hepatic ischemia/reperfusion injury. Curr Pharm Des 12:2867-2873, 2006.
6. Frangogiannis NG: Chemokines in ischemia and reperfusion. Thromb Haemost 97:738-747, 2007.
7. Martinez-Mier G, Toledo-Pereyra LH, Ward PA: Adhesion molecules in liver ischemia and reperfusion. J Surg Res 94:185-194, 2000.
8. Serracino-Inglott F, Habib NA, Mathie RT: Hepatic ischemia-reperfusion injury. Am J Surg 181:160-166, 2001.
9. Ayub K, Serracino-Inglott F, Williamson RC, Mathie RT: Expression of inducible nitric oxide synthase contributes to the development of pancreatitis following pancreatic ischaemia and reperfusion. Br J Surg 88:1189-1193, 2001.
10. Selzner N, Rudiger H, Graf R, Clavien PA: Protective strategies against ischemic injury of the liver. Gastroenterology 125:917-936, 2003.
11. Lee HT, Emala CW: Systemic adenosine given after ischemia protects renal function via A(2a) adenosine receptor activation. Am J Kidney Dis 38:610-618, 2001.
12. Okusa MD: A(2A) adenosine receptor: a novel therapeutic target in renal disease. Am J Physiol Renal Physiol 282:F10-F18, 2002.
13. Okusa MD, Linden J, Huang L, Rosin DL, Smith DF, Sullivan G: Enhanced protection from renal ischemia-reperfusion [correction of ischemia: reperfusion] injury with A(2A)-adenosine receptor activation and PDE 4 inhibition. Kidney Int 59:2114-2125, 2001.
14. Kobayashi T, Sugawara Y, Ohkubo T, Imamura H, Makuuchi M: Effects of amrinone on hepatic ischemia-reperfusion injury in rats. J Hepatol 37:31-38, 2002.
15. Ikegami T, Nishizaki T, Hiroshige S, Ohta R, Yanaga K, Sugimachi K: Experimental study of a type 3 phosphodiesterase inhibitor on liver graft function. Br J Surg 88:59-64, 2001.
16. Ishikawa H, Jin MB, Ogata T, Taniguchi M, Suzuki T, Shimamura T, Magata S, Horiuchi H, Ogata K, Masuko H, et al.: Role of cyclic nucleotides in ischemia and reperfusion injury of canine livers. Transplantation 73: 1041-1048, 2002.
17. Mizutani A, Murakami K, Okajima K, Kira S, Mizutani S, Kudo K, Takatani J, Goto K, Hattori S, Noguchi T: Olprinone reduces ischemia/reperfusion-induced acute renal injury in rats through enhancement of cAMP. Shock 24:281-287, 2005.
18. Sanada S, Kitakaze M, Papst PJ, Asanuma H, Node K, Takashima S, Asakura M, Ogita H, Liao Y, Sakata Y, et al.: Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors: the role of protein kinase A and p38 mitogen-activated protein kinase. Circulation 104:705-710, 2001.
19. Tosaka S, Makita T, Tosaka R, Maekawa T, Cho S, Hara T, Ureshino H, Sumikawa K: Cardioprotection induced by olprinone, a phosphodiesterase III inhibitor, involves phosphatidylinositol-3-OH kinase-Akt and a mitochondrial permeability transition pore during early reperfusion. J Anesth 21:176-180, 2007.
20. Sugawara Y, Kubota K, Ogura T, Esumi H, Inoue K, Takayama T, Makuuchi M: Increased nitric oxide production in the liver in the perioperative period of partial hepatectomy with Pringle's maneuver. J Hepatol 28:212-220, 1998.
21. Sugawara Y, Mizugaki Y, Uchida T, Torii T, Imai S, Makuuchi M, Takada K: Detection of Epstein-Barr virus (EBV) in hepatocellular carcinoma tissue: a novel EBV latency characterized by the absence of EBV-encoded small RNA expression. Virology 256:196-202, 1999.
22. Kihara K, Ueno S, Sakoda M, Aikou T: Effects of hyperbaric oxygen exposure on experimental hepatic ischemia reperfusion injury: relationship between its timing and neutrophil sequestration. Liver Transpl 11:1574-1580, 2005.
23. Kojima Y, Suzuki S, Tsuchiya Y, Konno H, Baba S, Nakamura S: Regulation of pro-inflammatory and anti-inflammatory cytokine responses by Kupffer cells in endotoxin-enhanced reperfusion injury after total hepatic ischemia. Transpl Int 16:231-240, 2003.
24. Krieglstein CF, Granger DN: Adhesion molecules and their role in vascular disease. Am J Hypertens 14:44S-54S, 2001.
25. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatter SW, et al.: A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372:739-746, 1994.
26. Underwood DC, Osborn RR, Kotzer CJ, Adams JL, Lee JC, Webb EF, Carpenter DC, Bochnowicz S, Thomas HC, Hay DW, et al.: SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. J Pharmacol Exp Ther 293:281-288, 2000.
27. Montalvo-Jave EE, Escalante-Tattersfield T, Ortega-Salgado JA, Pina E, Geller DA: Factors in the pathophysiology of the liver ischemia-reperfusion injury. J Surg Res 147:153-159, 2008.
28. Watanabe K, Kinoshita S, Nakagawa H: Purification and characterization of cytokine-induced neutrophil chemoattractant produced by epithelioid cell line of normal rat kidney (NRK-52E cell). Biochem Biophys Res Commun 161: 1093-1099, 1989.
29. Hisama N, Yamaguchi Y, Miyanari N, Ichiguchi O, Goto M, Mori K, Ogawa M: Ischemia-reperfusion injury: the role of Kupffer cells in the production of cytokine-induced neutrophil chemoattractant, a member of the interleukin-8 family. Transplant Proc 27:1604-1606, 1995.
30. Rothlein R, Dustin ML, Marlin SD, Springer TA: A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1. J Immunol 137:1270-1274, 1986.
31. Yadav SS, Howell DN, Gao W, Steeber DA, Harland RC, Clavien PA: L-Selectin and ICAM-1 mediate reperfusion injury and neutrophil adhesion in the warm ischemic mouse liver. Am J Physiol 275:G1341-G1352, 1998.
32. Nakano H, Kuzume M, Namatame K, Yamaguchi M, Kumada K: Efficacy of intraportal injection of anti-ICAM-1 monoclonal antibody against liver cell injury following warm ischemia in the rat. Am J Surg 170:64-66, 1995.
33. Marubayashi S, Oshiro Y, Maeda T, Fukuma K, Okada K, Hinoi T, Ikeda M, Yamada K, Itoh H, Dohi K: Protective effect of monoclonal antibodies to adhesion molecules on rat liver ischemia-reperfusion injury. Surgery 122: 45-52, 1997.
34. Raingeaud J, Gupta S, Rogers JS, Dickens M, Han J, Ulevitch RJ, Davis RJ: Pro-inflammatory cytokines and environmental stress cause p38 mitogen- activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem 270:7420-7426, 1995.
35. Chan ED, Winston BW, Jarpe MB, Wynes MW, Riches DW: Preferential activation of the p46 isoform of JNK/SAPK in mouse macrophages by TNF alpha. Proc Natl Acad Sci U S A 94:13169-13174, 1997.
36. Bendinelli P, Piccoletti R, Maroni P, Bernelli-Zazzera A: The MAP kinase cascades are activated during post-ischemic liver reperfusion. FEBS Lett 398:193-197, 1996.
37. Schwertz H, Carter JM, Abdudureheman M, Russ M, Buerke U, Schlitt A, Muller-Werdan U, Prondzinsky R, Werdan K, Buerke M: Myocardial ischemia/ reperfusion causes VDAC phosphorylation which is reduced by cardioprotection with a p38 MAP kinase inhibitor. Proteomics 7:4579-4588, 2007.
38. Doucet C, Milin S, Favreau F, Desurmont T, Manguy E, Hebrard W, Yamamoto Y, Mauco G, Eugene M, Papadopoulos V, et al.: A p38 mitogen-activated protein kinase inhibitor protects against renal damage in a non- heart-beating donor model. Am J Physiol Renal Physiol 295:F179-F191, 2008.
39. Ishii M, Suzuki Y, Takeshita K, Miyao N, Kudo H, Hiraoka R, Nishio K, Sato N, Naoki K, Aoki T, et al.: Inhibition of c-Jun NH2-terminal kinase activity improves ischemia/reperfusion injury in rat lungs. J Immunol 172: 2569-2577, 2004.
40. Ferrandi C, Ballerio R, Gaillard P, Giachetti C, Carboni S, Vitte PA, Gotteland JP, Cirillo R: Inhibition of c-Jun N-terminal kinase decreases cardiomyocyte apoptosis and infarct size after myocardial ischemia and reperfusion in anaesthetized rats. Br J Pharmacol 142:953-960, 2004.
41. Guha M, Mackman N: LPS induction of gene expression in human monocytes. Cell Signal 13:85-94, 2001.
42. Novitskiy G, Ravi R, Potter JJ, Rennie-Tankersley L, Wang L, Mezey E: Effects of acetaldehyde and TNFa on the inhibitory kappa BY! protein and nuclear factor kappa B activation in hepatic stellate cells. Alcohol Alcohol 40:96-101, 2005.
43. Okaya T, Lentsch AB: Cytokine cascades and the hepatic inflammatory response to ischemia and reperfusion. J Invest Surg 16:141-147, 2003.
44. Meng X, Ao L, Shames BD, Harken AH: Inhibition of cyclic-3',5'-nucleotide phosphodiesterase abrogates the synergism of hypoxia with lipopolysaccharide in the induction of macrophage TNF-alpha production. J Surg Res 101:210-215, 2001.
45. Gu Q, Yang XP, Bonde P, DiPaula A, Fox-Talbot K, Becker LC: Inhibition of TNF-alpha reduces myocardial injury and proinflammatory pathways following ischemia-reperfusion in the dog. J Cardiovasc Pharmacol 48:320-328, 2006.
46. Kume M, Banafsche R, Yamamoto Y, Yamaoka Y, Nobiling R, Gebhard MM, Klar E: Dynamic changes of post-ischemic hepatic microcirculation improved by a pre-treatment of phosphodiesterase-3 inhibitor, milrinone. J Surg Res 136: 209-218, 2006.
47. Iribe G, Yamada H, Matsunaga A, Yoshimura N: Effects of the phosphodiesterase III inhibitors olprinone, milrinone, and amrinone on hepatosplanchnic oxygen metabolism. Crit Care Med 28:743-748, 2000.